125 filings
Page 2 of 7
6-K
ak5zj 72xnm4o5hq1t1
18 Aug 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:07pm
6-K
b5xiolytxe7k sn6
12 Aug 20
Genmab Announces Financial Results for the First Half of 2020
3:22pm
6-K
e80u ccumc
31 Jul 20
Current report (foreign)
4:49pm
6-K
a3gzw0qwee
20 Jul 20
Major Shareholder Announcement
1:09pm
6-K
8hx1ka
16 Jul 20
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
10:05am
6-K
2kul12ar5ejcbgat77
7 Jul 20
Major Shareholder Announcement
11:19am
6-K
s6gf oc2qiv0b91
6 Jul 20
Major Shareholder Announcement
1:57pm
6-K
4w10ox
6 Jul 20
Major Shareholder Announcement
1:54pm
6-K
kupqb j7d8b1n1t4tza
1 Jul 20
Current report (foreign)
10:58am
6-K
q9e01m61c b1
30 Jun 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:16pm
6-K
uui48e3i
29 Jun 20
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
12:00am
6-K
t5m19
11 Jun 20
Current report (foreign)
9:40am
6-K
7m2gr 1b7dd
10 Jun 20
Genmab and AbbVie Announce Broad Oncology Collaboration
7:33am
6-K
v1awhbx
4 Jun 20
Subcutaneous fixed-dosed formulation of DARZALEX® (daratumumab) approved in Europe for the treatment of adult patients with multiple myeloma
10:55am
6-K
flplbkno2xkcqr5tz
3 Jun 20
Current report (foreign)
4:48pm
6-K
ibslebs0
28 May 20
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
4:14pm
6-K
tcjfi8cp fppbc
13 May 20
Current report (foreign)
2:47pm
6-K
spb6hcaudj9ykmgvv
12 May 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2:00pm
6-K
mgvwilu2 5ml2w470om
6 May 20
Genmab Announces Financial Results for the First Quarter of 2020
2:31pm
6-K
tya5b0y
1 May 20
Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple myeloma
3:02pm